Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.04 USD | +9.30% | -0.71% | -18.17% |
10/05 | UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating | MT |
09/05 | Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.17% | 284.54Cr | |
+7.52% | 11TCr | |
+11.38% | 11TCr | |
-12.64% | 2.22TCr | |
+0.44% | 2.13TCr | |
-4.18% | 1.9TCr | |
-37.85% | 1.85TCr | |
-8.58% | 1.68TCr | |
+37.41% | 1.25TCr | |
-23.95% | 808.97Cr |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- RBC Capital Adjusts Price Target on Arrowhead Pharmaceuticals to $77 From $83 on Hepatitis B Virus Therapy Deprioritization, Keeps Outperform Rating